Gland Pharma shares reached a new 52-week high after the company reported strong results for the March quarter and full year. The European unit Cenexi showed signs of recovery while new product launches and capacity additions supported the outlook.
Gland Pharma stock climbed to its highest level in a year following the release of robust quarterly and annual figures. The company highlighted improving profitability at its European subsidiary Cenexi as a key positive factor.